ライフサイエンスコーパス: percutaneous

1 Background Percutaneous ablation for cT1 renal cell carcinoma (RCC)

2 s (410 resections, 137 transplantations, 122 percutaneous ablations, and 52 noncurative) for 190 gene

3 f FM, including extracorporeal life support, percutaneous and durable ventricular assist devices, tra

4 nsus guidelines have recommended surgical or percutaneous ASD closure in adults with right heart enla

5 Percutaneous axillary access for use with microaxial sup

6 isolated mitral stenosis often benefit from percutaneous balloon mitral valvuloplasty.

7 ts who underwent real-time ultrasound-guided percutaneous biopsies of space-occupying liver lesions w

8 8)F-FDG PET/CT and CT performance in guiding percutaneous biopsies with histologic confirmation of lu

9 gether with important considerations for the percutaneous closure of PVL, such as access site and dev

10 Percutaneous coronary angioplasty versus coronary artery

11 n the therapy than control immediately after percutaneous coronary intervention (14.1+/-4.1% versus 1

12 y coronary angiography (49.2% versus 54.1%), percutaneous coronary intervention (59.2% versus 64.0%),

13 lts were confirmed among patients undergoing percutaneous coronary intervention (72% of population) a

14 lected in the Diagnostic Catheterization and Percutaneous Coronary Intervention (CathPCI) registry of

15 Icosapent ethyl significantly reduced percutaneous coronary intervention (hazard ratio, 0.68 [

16 l infarction (HR, 0.72 [95% CI, 0.59-0.90]), percutaneous coronary intervention (HR, 0.78 [95% CI, 0.

17 tion dose during cardiac catheterization and percutaneous coronary intervention (n=632) with or witho

18 the benefit of urgent coronary angiogram and percutaneous coronary intervention (PCI) after sudden ca

19 ur despite successful revascularisation with percutaneous coronary intervention (PCI) and antianginal

20 Its effect on payments and outcomes for percutaneous coronary intervention (PCI) and coronary ar

21 edural myocardial infarction (PMI) following percutaneous coronary intervention (PCI) and coronary by

22 Vascular injury and inflammation during percutaneous coronary intervention (PCI) are associated

23 r adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) are believed to

24 regimens in patients who undergo multivessel percutaneous coronary intervention (PCI) are sparse.

25 in-hospital outcomes of patients undergoing percutaneous coronary intervention (PCI) for ISR in the

26 e were randomly assigned (1:1) to either the percutaneous coronary intervention (PCI) group or corona

27 Although results of percutaneous coronary intervention (PCI) have been stead

28 ies examining sex-related outcomes following percutaneous coronary intervention (PCI) have reported c

29 CATH was followed by percutaneous coronary intervention (PCI) in cases of sig

30 (LRPV), are increasingly revascularized with percutaneous coronary intervention (PCI) in contemporary

31 An evolving strategy in the setting of percutaneous coronary intervention (PCI) involves withdr

32 intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) irrespective of

33 Undergoing percutaneous coronary intervention (PCI) is a risk facto

34 Percutaneous coronary intervention (PCI) is increasingly

35 h nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is unclear.

36 s remains true in patients with a history of percutaneous coronary intervention (PCI) is unknown.

37 tatus outcomes after chronic total occlusion percutaneous coronary intervention (PCI) is unknown.

38 Complications of percutaneous coronary intervention (PCI) may have signif

39 , this relationship has not been studied for percutaneous coronary intervention (PCI) of chronic tota

40 This study sought to examine the outcomes of percutaneous coronary intervention (PCI) of non-flow-lim

41 rly PCI for STEMI) trial, angiography-guided percutaneous coronary intervention (PCI) of nonculprit l

42 nts (MACE) compared with aspirin alone after percutaneous coronary intervention (PCI) or acute corona

43 disease benefit from revascularization with percutaneous coronary intervention (PCI) or coronary art

44 uracy of a novel noninvasive FFR(CT)-derived percutaneous coronary intervention (PCI) planning tool (

45 tive of the study was to evaluate changes in percutaneous coronary intervention (PCI) practice in Eng

46 mpare a large cohort of R-PCI to traditional percutaneous coronary intervention (PCI) procedures perf

47 ST-segment-elevation myocardial infarction, percutaneous coronary intervention (PCI) reduces mortali

48 cute coronary syndrome (ACS) treated without percutaneous coronary intervention (PCI) remains unexplo

49 s across US hospitals in patients undergoing percutaneous coronary intervention (PCI) treated with MC

50 t main coronary artery disease randomized to percutaneous coronary intervention (PCI) versus coronary

51 Surgery) trial, the effect of treatment with percutaneous coronary intervention (PCI) versus coronary

52 Long-term outcomes after percutaneous coronary intervention (PCI) with contempora

53 real-world observational evidence comparing percutaneous coronary intervention (PCI) with coronary a

54 omic complexity of patients that may undergo percutaneous coronary intervention (PCI) without on-site

55 ts) infusion before, and following, emergent percutaneous coronary intervention (PCI), or to a contro

56 marker-negative patients undergoing elective percutaneous coronary intervention (PCI), periprocedural

57 revascularization is accomplished either by percutaneous coronary intervention (PCI), with low risk

58 closure device (VCD) are thought to mitigate percutaneous coronary intervention (PCI)-related bleedin

59 myocardial ischemia and guide decisions for percutaneous coronary intervention (PCI).

60 ing (CABG) has shown long-term benefits over percutaneous coronary intervention (PCI).

61 dial infarction (NSTEMI) patients treated by percutaneous coronary intervention (PCI).

62 DR for preventing AKI in patients undergoing percutaneous coronary intervention (PCI).

63 ood pressure and long-term outcome following percutaneous coronary intervention (PCI).

64 ostic effects of FFR measured directly after percutaneous coronary intervention (PCI).

65 d outcomes with CA among patients undergoing percutaneous coronary intervention (PCI).

66 undergoing coronary angiography and possible percutaneous coronary intervention (PCI).

67 FR) provides decision-making guidance during percutaneous coronary intervention (PCI).

68 me of patients with STEMI treated by primary percutaneous coronary intervention (PPCI), with identifi

69 risk of occupational exposure during primary percutaneous coronary intervention (PPCI).

70 dial infarction scheduled to undergo primary percutaneous coronary intervention (pPCI).

71 Robotic percutaneous coronary intervention (R-PCI) has been show

72 nd survival after unprotected left main stem percutaneous coronary intervention (uLMS-PCI) is poorly

73 wing a coronary revascularization procedure (percutaneous coronary intervention [PCI] or coronary art

74 admissions (ie, coronary angiography without percutaneous coronary intervention [PCI], PCI, and coron

75 f the primary safety end point of major peri-percutaneous coronary intervention adverse events was si

76 heart valve and underwent CA with or without percutaneous coronary intervention after TAVI.

77 on thrombectomy catheter devices used during percutaneous coronary intervention among 95 925 patients

78 were >5 times the upper reference level for percutaneous coronary intervention and >10 times for cor

79 T-segment elevation MI who underwent primary percutaneous coronary intervention and the interplay bet

80 component of dual antiplatelet therapy after percutaneous coronary intervention and the withholding o

81 A total of 19 348 patients underwent primary percutaneous coronary intervention and were included in

82 with acute myocardial infarction undergoing percutaneous coronary intervention are at increased risk

83 Thus, post-TAVI coronary access (CA) and percutaneous coronary intervention are expected to incre

84 es when delays in timely delivery of primary percutaneous coronary intervention are expected, a moder

85 leeding and myocardial infarction (MI) after percutaneous coronary intervention are independent risk

86 ion myocardial infarction undergoing primary percutaneous coronary intervention are limited.

87 ed with confirmed STEMI treated with primary percutaneous coronary intervention at Barts Heart Centre

88 nning zones and was performed before primary percutaneous coronary intervention by an operator blinde

89 s a steep increase in mortality when primary percutaneous coronary intervention cannot be delivered i

90 , stroke, pericardial effusion or tamponade, percutaneous coronary intervention due to iatrogenic cor

91 to the left anterior descending artery with percutaneous coronary intervention for non-left anterior

92 tems designed to perform expeditious primary percutaneous coronary intervention for patients presenti

93 monitored biomarker concentrations regarding percutaneous coronary intervention for prognostic purpos

94 alysis was limited only to studies that used percutaneous coronary intervention for revascularization

95 ly selected high-risk patients after primary percutaneous coronary intervention for ST-segment-elevat

96 Among patients undergoing percutaneous coronary intervention for ST-segment-elevat

97 Among 10 987 patients treated with percutaneous coronary intervention for stable ischemic h

98 equiring inter-hospital transfer for primary percutaneous coronary intervention from 12 regions aroun

99 ervention Society including all the elective percutaneous coronary intervention from 2007 to 2014 in

100 ion myocardial infarction undergoing primary percutaneous coronary intervention from 2011 to 2018 wer

101 % of women and 55% of men in the multivessel percutaneous coronary intervention group.

102 acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding wit

103 Bleeding following percutaneous coronary intervention has important prognos

104 High bleeding risk (HBR) patients undergoing percutaneous coronary intervention have been widely excl

105 rvention of nonculprit lesions after primary percutaneous coronary intervention improves outcomes in

106 2 coronary arteries before nonculprit lesion percutaneous coronary intervention in 93 patients with S

107 Among 7888 patients who underwent percutaneous coronary intervention in Alberta Canada, CA

108 rit-lesion-only versus immediate multivessel percutaneous coronary intervention in patients presentin

109 aspirin after an acute coronary syndrome or percutaneous coronary intervention in patients with atri

110 ing total ischemic and bleeding events after percutaneous coronary intervention in the GLOBAL LEADERS

111 s-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by

112 py (DAPT) cessation and adverse events after percutaneous coronary intervention is unknown.

113 Incorporation of this strategic method for percutaneous coronary intervention may aid in the greate

114 to incorporating intravascular imaging with percutaneous coronary intervention may overcome the barr

115 In patients undergoing percutaneous coronary intervention of de novo saphenous

116 Complete revascularization with routine percutaneous coronary intervention of nonculprit lesions

117 This may help explain the benefit of routine percutaneous coronary intervention of obstructive noncul

118 llowing revascularization strategies: either percutaneous coronary intervention of the culprit-lesion

119 lation and recent acute coronary syndrome or percutaneous coronary intervention on a P2Y(12) inhibito

120 ention) or control (50 patients treated with percutaneous coronary intervention only).

121 on coronary angiography managed with either percutaneous coronary intervention or medical therapy.

122 ilar to their performances in the derivation percutaneous coronary intervention populations.

123 .6% were active smokers at the time of their percutaneous coronary intervention procedure.

124 in 2.5% and 2.1% of coronary angiography and percutaneous coronary intervention procedures, respectiv

125 lation and recent acute coronary syndrome or percutaneous coronary intervention receiving a P2Y(12) i

126 e patients in New York's cardiac surgery and percutaneous coronary intervention registries in 2010 to

127 Primary percutaneous coronary intervention resulted indicated in

128 quiring inter-hospital transfers for primary percutaneous coronary intervention that reflects inter-f

129 month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention to conventional 12-mo

130 has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the incid

131 Veterans Affairs centers within 72 hours of percutaneous coronary intervention to intensive lipid-lo

132 tion services, and had higher AMI volume and percutaneous coronary intervention use during the AMI ho

133 The clinical success of percutaneous coronary intervention was 97.9%.

134 -dose intracoronary alteplase during primary percutaneous coronary intervention was associated with i

135 tegy was used in 163 patients (60.4%), and a percutaneous coronary intervention was performed in 97 p

136 erformed, and in the coronary arteries where percutaneous coronary intervention was performed.

137 Prior percutaneous coronary intervention was the strongest cli

138 Patients in the downstream group undergoing percutaneous coronary intervention were further randomiz

139 Percutaneous coronary intervention with a drug-eluting s

140 iving 30-day dual antiplatelet therapy after percutaneous coronary intervention with a polymer-free d

141 larization) were assessed and compared after percutaneous coronary intervention with bare-metal stent

142 a and 30-day dual antiplatelet therapy after percutaneous coronary intervention with DCS, identical t

143 tor monotherapy reduces major bleeding after percutaneous coronary intervention with drug-eluting ste

144 on of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting ste

145 PT; and extended-term (>12-month) DAPT after percutaneous coronary intervention with drug-eluting ste

146 iplatelet therapy in HBR patients undergoing percutaneous coronary intervention with Resolute Onyx dr

147 the association of all-cause mortality after percutaneous coronary intervention with site-reported bl

148 In the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardia

149 ctiveness of 1-month DAPT duration following percutaneous coronary intervention with zotarolimus-elut

150 itals was associated with performing primary percutaneous coronary intervention within the national g

151 underwent cardiac catheterization (139 with percutaneous coronary intervention) in the setting of OA

152 0 patients treated with sonothrombolysis and percutaneous coronary intervention) or control (50 patie

153 rillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atria

154 with coronary artery bypass graft surgery or percutaneous coronary intervention).

155 ion myocardial infarction undergoing primary percutaneous coronary intervention, admission LUS added

156 less likely to receive coronary angiography, percutaneous coronary intervention, and mechanical circu

157 l therapy in high-risk patients with primary percutaneous coronary intervention, based on one of the

158 leles impair clopidogrel effectiveness after percutaneous coronary intervention, but the clinical imp

159 In patients undergoing percutaneous coronary intervention, CEC procedures ident

160 long-term MACE after revascularization with percutaneous coronary intervention, even with contempora

161 ital mortality, use of coronary angiography, percutaneous coronary intervention, mechanical circulato

162 Use of coronary angiography, percutaneous coronary intervention, mechanical circulato

163 n, that is, coronary artery bypass grafting, percutaneous coronary intervention, or equipoise coronar

164 At the time of percutaneous coronary intervention, participants were ra

165 ion myocardial infarction undergoing primary percutaneous coronary intervention, there was no signifi

166 schemic and bleeding events at 2 years after percutaneous coronary intervention, ticagrelor monothera

167 orting the use of intravascular imaging with percutaneous coronary intervention, utilization remains

168 er bivalirudin or heparin monotherapy during percutaneous coronary intervention, with mandatory poten

169 defined as <=120 minutes from arrival at the percutaneous coronary intervention-capable facility.

170 day discharge (SDD) following uncomplicated percutaneous coronary intervention.

171 reater adoption of intravascular imaging for percutaneous coronary intervention.

172 cute coronary syndrome patients treated with percutaneous coronary intervention.

173 cal options when treating patients following percutaneous coronary intervention.

174 rategy for shortened DAPT duration following percutaneous coronary intervention.

175 n myocardial infarction treated with primary percutaneous coronary intervention.

176 ion myocardial infarction undergoing primary percutaneous coronary intervention.

177 dose, on IPA in patients undergoing primary percutaneous coronary intervention.

178 ion myocardial infarction undergoing primary percutaneous coronary intervention.

179 h dual antiplatelet therapy (DAPT) following percutaneous coronary intervention.

180 ranging trial in patients undergoing primary percutaneous coronary intervention.

181 hen selecting antiplatelet therapy following percutaneous coronary intervention.

182 on-only as compared to immediate multivessel percutaneous coronary intervention.

183 equiring inter-hospital transfer for primary percutaneous coronary intervention.

184 contemporary group of patients who underwent percutaneous coronary intervention.

185 cute coronary syndrome patients treated with percutaneous coronary intervention.

186 monotherapy appeared to be beneficial after percutaneous coronary intervention.

187 IMR, CFR, and RRR were measured post-primary percutaneous coronary intervention.

188 directions for adoption of the technique in percutaneous coronary intervention.

189 ls of patients with STEMI undergoing primary percutaneous coronary intervention.

190 ute coronary syndromes, and those undergoing percutaneous coronary intervention.

191 n all-comers patient population treated with percutaneous coronary intervention.

192 l-comers trial of 15 968 patients undergoing percutaneous coronary intervention.

193 erse events during the first month following percutaneous coronary intervention.

194 udy, 185 (32%) patients underwent stent-only percutaneous coronary intervention.

195 ysis in Myocardial Infarction) flow <3 after percutaneous coronary intervention.

196 n strategies toward these individuals during percutaneous coronary intervention.

197 culprit-lesion-only or immediate multivessel percutaneous coronary intervention.

198 farction (STEMI) patients treated by primary percutaneous coronary intervention.

199 or equipoise coronary artery bypass grafting-percutaneous coronary intervention.

200 erse cardiovascular events, especially after percutaneous coronary intervention.

201 rapy with P2Y12 inhibitors in patients after percutaneous coronary intervention.

202 e during routine cardiac catheterization and percutaneous coronary intervention.

203 e treatment strategy from medical therapy to percutaneous coronary intervention.

204 age 61 years, 209 women) undergoing primary percutaneous coronary intervention.

205 from 44% to 75% among patients who underwent percutaneous coronary intervention.

206 ansitioned to predominantly SDD for elective percutaneous coronary intervention.

207 ld change antiplatelet prescribing following percutaneous coronary intervention.The primary outcome w

208 round of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review

209 and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUST

210 oronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention; NCT00097591).

211 ass surgery; heart valve repair/replacement; percutaneous coronary intervention; or heart/heart-lung

212 ne electrocardiographic monitoring following percutaneous coronary interventions (PCI) is not well st

213 After percutaneous coronary interventions (PCIs), patients rem

214 itals evaluated, 1440 (79.4%) performed >=10 percutaneous coronary interventions annually.

215 an adjunct to coronary angiography to guide percutaneous coronary interventions has accumulated over

216 The role of percutaneous coronary interventions in addition to medic

217 g routine cardiac catheterization, including percutaneous coronary interventions.

218 coronary syndromes in the setting of primary percutaneous coronary interventions.

219 to reduce operator radiation exposure during percutaneous coronary procedures Methods and Results: Th

220 r Table to Reduce Operator Radiation Dose in Percutaneous Coronary Procedures) is a prospective, sing

221 ow is observed in ~30% of CAD patients after percutaneous coronary stenting and is associated with a

222 Background Percutaneous cryoablation (PCA) is an increasingly utili

223 Overall survival probability after percutaneous cryoablation at 5 years and 10 years was lo

224 tution study assessed patients who underwent percutaneous cryoablation for solitary pathology-proven

225 diate- to long-term outcomes of image-guided percutaneous cryoablation of cT1 RCC and to compare outc

226 Conclusion Percutaneous cryoablation yielded a 10-year disease-spec

227 Conclusion Percutaneous CT- and MRI-guided cryoablation of cT1 rena

228 Although recent percutaneous device advancements have incorporated thinn

229 Both open surgical and percutaneous dilational tracheostomy techniques were per

230 0.526), mortality (4.0% vs 3.3%, P = 0.576), percutaneous drainage (12% vs 12%, P = 0.809), reoperati

231 BEST PRACTICE ADVICE 7: Percutaneous drainage and transmural endoscopic drainage

232 BEST PRACTICE ADVICE 8: Percutaneous drainage of pancreatic necrosis should be c

233 ADVICE 15: A step-up approach consisting of percutaneous drainage or endoscopic transmural drainage

234 Ultrasound-guided percutaneous drainage revealed "anchovy sauce" pus.

235 Percutaneous drainage should be strongly considered as a

236 tive times, increased need for postoperative percutaneous drainage, antibiotics at discharge, parente

237 for: DSM, CR-POPF, delayed gastric emptying, percutaneous drainage, length of stay, and readmission.

238 behavioural therapy), diet (probiotics) and percutaneous electrical nerve field stimulation.

239 the ability to safely and successfully place percutaneous electrical phrenic nerve stimulation leads

240 ssed the safety and feasibility of temporary percutaneous electrical phrenic nerve stimulation on use

241 Percutaneous electrical phrenic nerve stimulation was us

242 Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes

243 tion transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repa

244 CMO, 203 (0.8%) with TCS-VAD, 44 (0.2%) with percutaneous endovascular devices, and 8 (0.03%) with Ta

245 blood borne pathogen mostly transmitted via percutaneous exposure that results in inflammation of th

246 use only, IABP only, other (such as use of a percutaneous extracorporeal ventricular assist system, e

247 October 2019 with collimated-beam CT-guided percutaneous FICS procedures for preventive consolidatio

248 Results A total of 107 percutaneous FICS procedures were performed from 2010 to

249 ith pathologic pelvic fractures managed with percutaneous FICS.

250 tive durability of collimated-beam CT-guided percutaneous fixation with internal cemented screws (FIC

251 Conclusion Percutaneous fixation with internal cemented screws as p

252 al hepatectomy for solitary metastases, with percutaneous hepatic perfusion with melphalan or with te

253 Promising results in feasibility trials with percutaneous image-guided tissue sampling for the identi

254 dritic epidermal T cells, and an exaggerated percutaneous immune response.

255 utees were implanted with an osseointegrated percutaneous implant system for direct skeletal attachme

256 n Myocardial Infarction Referred for Primary Percutaneous Intervention) is an investigator-initiated,

257 ons were treated by spontaneous, surgical or percutaneous interventional procedures.

258 se To investigate the safety and efficacy of percutaneous IRE for locally advanced pancreatic cancer

259 arget median overall survival with CT-guided percutaneous irreversible electroporation was exceeded i

260 Percutaneous left atrial appendage closure (LAAC) is non

261 icacy and complications of ultrasound-guided percutaneous liver biopsy in the diagnosis of space-occu

262 Ultrasound-guided percutaneous liver biopsy is an efficacious and safe tec

263 Ultrasound-guided percutaneous liver biopsy is considered the technique of

264 lug on the rate of pneumothorax at CT-guided percutaneous lung biopsy.

265 for in vivo tissue classification during the percutaneous needle biopsy (PNB) of the liver.

266 , atypical ductal hyperplasia diagnosed with percutaneous needle biopsy should be managed with surgic

267 n was lower than previous reports (33.7% for percutaneous needle fasciotomy, 19.5% for limited fascie

268 Pigs underwent transient percutaneous occlusion of the left coronary artery and w

269 , and there are several novel catheter-based percutaneous options in clinical trials.

270 Percutaneous options, while promising, must be deployed

271 tabases to assess the effect of secundum ASD percutaneous or surgical closure in unoperated adults >=

272 table cryptogenic stroke who were undergoing percutaneous PFO closure were followed for up to 11 year

273 Percutaneous pulmonary valve implantation (PPVI) has bec

274 Background Percutaneous radiofrequency ablation (RFA) is effective

275 es, and less frequent history of surgical or percutaneous revascularization compared with men.

276 Even though the respiratory and percutaneous routes are well documented and considered t

277 p imaging, 38 of 196 (19%) lesions underwent percutaneous sampling, and 38 of 38 (100%) revealed beni

278 aging, and 38 of 196 (20%) lesions underwent percutaneous sampling.

279 oscopic tissue removal, one patient received percutaneous sclerotherapy and one patient received a co

280 ic AD, eAD), and established ovalbumin (OVA) percutaneous sensitized AD model and passive cutaneous a

281 We review the pathophysiology, percutaneous therapeutic treatment options, and ongoing

282 Recently, advances in percutaneous therapies for carotid artery disease have b

283 In addition to OAC, non-pharmacological, percutaneous therapies, including left atrial appendage

284 ascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Fun

285 ascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Fun

286 ascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Fun

287 ascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Fun

288 ascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Fun

289 ascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Fun

290 liver metastasis, and the surveillance after percutaneous therapy.

291 Patients had either a percutaneous tracheostomy (PT) or open surgical tracheos

292 Percutaneous trans-thoracic lung (LA) and pleural fluid

293 Standard percutaneous transluminal angioplasty is the current rec

294 After successful high-pressure percutaneous transluminal angioplasty, participants were

295 The next day, she underwent successful percutaneous transluminal balloon angioplasty with an io

296 s were treated with medical therapy (MT) and percutaneous transluminal renal angioplasty (MT + PTRA)

297 s study was to evaluate the feasibility of a percutaneous transseptal transcatheter mitral valve repl

298 safety of mechanical circulatory support via percutaneous upper-extremity access.

299 apoptosis, together with urgent surgical or percutaneous valve interventions.

300 tion, this study demonstrated that the MANTA percutaneous vascular closure device can safely and effe